CAT
Caterpillar Inc.
CAT has the edge over EML overall, supported by stronger modeled upside and stronger fundamentals.
EML
The Eastern Company
EML trails on the overall score without a compensating advantage in the available component scores.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
EML Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Under pressure | |
| Stable |
EML's revenue and profitability are currently healthy, and its balance sheet is stable, but its cash flow is under pressure.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
EML PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $16.97 | -45% |
| Fair | 14x | $25.80 | -16% |
| Current | 17x | $30.81 | — |
| Expensive | 21x | $37.74 | +23% |
Historical ranges are pointers, not guarantees.
EML has the edge over CAT in the historical PE scenario, which offers more potential upside but is not a forecast.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
EML Forward outlook
There aren't enough analyst estimates for EML to show an outlook.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT earned $25.48 per share over the past year, up 31% from the year before.
EML Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.81 | +51% |
| Q2 2026 | $1.34 | +$2.70 |
| Q1 2026 | $0.96 | +$2.32 |
| Q4 2025 | $1.17 | +$2.54 |
| Q3 2025 | $1.20 | +$2.23 |
| Q2 2025 | -$1.36 | -171% |
| Q1 2025 | -$1.36 | -186% |
| Q4 2024 | -$1.37 | -200% |
EML has the edge over CAT on earnings, with more consistent year-over-year improvement.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT has the edge over EML on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over EML on profitability, with a higher operating margin.
EML Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $75M | +35% |
| Q2 2026 | $61.8M | -12% |
| Q1 2026 | $59.7M | -5.7% |
| Q4 2025 | $57.5M | -14% |
| Q3 2025 | $55.3M | -22% |
| Q2 2025 | $70.2M | -4.1% |
| Q1 2025 | $63.3M | -6.8% |
| Q4 2024 | $66.7M | -0.5% |
EML's revenue has held roughly level: $75M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.4% | +4.3 points |
| Q2 2026 | 2.7% | -1.8 points |
| Q1 2026 | 2.2% | -2.9 points |
| Q4 2025 | 3.8% | -0.7 points |
| Q3 2025 | 3.1% | -6.4 points |
| Q2 2025 | 4.5% | -2.9 points |
| Q1 2025 | 5.1% | +0.2 points |
| Q4 2024 | 4.5% | -3.5 points |
EML's operating margin was 7.4% last quarter, up 4.3 points from the same quarter a year ago.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
EML Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4M | -232% |
| Q2 2026 | $7.9M | +164% |
| Q1 2026 | $2.6M | +$5.3M |
| Q4 2025 | $1.5M | -83% |
| Q3 2025 | $3.1M | +$9.8M |
| Q2 2025 | $3M | -47% |
| Q1 2025 | -$2.7M | -250% |
| Q4 2024 | $9M | +62% |
EML usually generates cash, though not every quarter: the latest was −$4M, but it generated $8M over the past year.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over EML on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
EML Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -1.4K shares |
| 1 year | -0.9% | -54.2K shares |
| 3 years | -3.9% | -245K shares |
| 5 years | -3.9% | -243K shares |
| Available history | -3.8% | -241K shares |
EML has 6M diluted shares, down 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $405,518 |
| Q1 2026 | $422,355 |
| Q4 2025 | $754,316 |
| Q3 2025 | $851,447 |
| Q2 2025 | $722,901 |
| Q1 2025 | $1.4M |
| Q2 2024 | $247,320 |
EML spent $2M buying back its own shares over the past year.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has the edge over EML on leverage, with a lower net debt burden relative to earnings.
EML Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.8x | Healthy |
| Q2 2026 | 2.0x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.2x | Healthy |
EML's net debt is about 1.8 years of its operating earnings (EBITDA), up from 1.5 years a year ago.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
EML Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.5 | Neutral |
| Stochastic | 66.3 | Neutral |
EML's weekly RSI is 65 (neutral) and its Stochastic is 66 (neutral).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
EML PE vs Industrials Sector
| Metric | EML | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 24x | 29% below |
| PE % | 67 | 58 | 9 pts above |
EML has the edge over CAT on valuation relative to its sector.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
EML Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.9 | 19% above |
| 20 week MA | $25.7 | 20% above |
| 50 week MA | $22.5 | 37% above |
| 100 week MA | $23.2 | 33% above |
| 200 week MA | $23.4 | 31% above |
EML has the edge over CAT on trend strength, trading above more of its moving averages.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has finished every year since 2020 higher, and it's up 3.8% so far in 2026.
EML Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.0 | $24.6 | -18% |
| 2021 | $24.6 | $24.8 | +0.8% |
| 2022 | $24.8 | $20.3 | -18% |
| 2023 | $20.3 | $22.0 | +8.4% |
| 2024 | $22.0 | $26.6 | +21% |
| 2025 | $26.6 | $20.5 | -23% |
| 2026 YTD | $20.5 | $30.8 | +51% |
EML has the edge over CAT on returns for 2026, with the stronger performance.